Cambridge, United States
Mersana Therapeutics, founded in 2001, is a visionary player in the Biotechnology and Health Care sectors, headquartered in the United States. With its mission, "Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fighting cancer," the company stands at the forefront of developing innovative treatments for cancer patients.
This clinical-stage biopharmaceutical enterprise is pioneering the development of novel antibody-drug conjugates (ADCs) through its proprietary Dolasynthen and Immunosynthen ADC platforms. These platforms are integral to its pipeline of wholly-owned and partnered product candidates aiming to address various cancer types. Notable projects include XMT-1660, targeting B7-H4, and XMT-2056, a novel HER2-targeting ADC.
Significant validation of Mersana's potential came with a $129.00M acquisition investment by Day One Biopharmaceuticals on 01 November 2025, marking a strategic move that underscores investor confidence in its robust pipeline and proprietary technologies.
